インフルエンザワクチンの世界市場：2025年～2033年

世界のインフルエンザワクチンの市場規模は、2024年に57億米ドルに達し、2033年には107億4,000万米ドルに達すると予測され、予測期間の2025年～2033年のCAGRは7.3％と見込まれています。

インフルエンザワクチンは、インフルエンザウイルスから身体を守るワクチンです。医療従事者が筋肉や皮膚にワクチンを注入し、免疫系がインフルエンザウイルスに対する抗体を産生するよう促します。医療従事者は「インフルエンザ予防接種」ワクチンを、皮膚から筋肉に注射する1回分の液体として投与します。インフルエンザワクチンには、不活化ワクチン、弱毒生ワクチン、組み換えワクチンなど、さまざまな種類があります。

より広範なインフルエンザ株に対する防御を提供するワクチンなど、革新的なワクチンの導入は、インフルエンザワクチン市場の成長に好影響を与えると予想されます。アジュバントワクチンのようなこれらの進歩は、免疫反応を強化し、予防効果をより長く持続させることができるため、頻繁なワクチン接種の必要性を低減できる可能性があります。

各社は、より多くの人々に優れた予防効果を提供するため、こうした新規ワクチンの開発に積極的に取り組んでいます。例えば、2023年10月、MylabとSerum Institute of India（SII）は、WHOの勧告に沿った4種類のインフルエンザウイルス株を標的とした、インド初の無針鼻腔インフルエンザワクチンであるNasovac S4を発売しました。

さらに、2023年9月には、Cadila Pharmaceuticalsが、広範なインフルエンザ感染の予防を目的とした先進的な4価インフルエンザワクチンであるCadiflu Tetra Vaccineを発表しました。こうした技術革新はヘルスケアプロバイダーや個人の注目を集め、効率的な予防接種ソリューションへの需要を押し上げ、予測期間中の市場の成長を促進するとみられます。

インフルエンザワクチンの高価格と、特定の年齢以下の小児や予防接種を受けたことのない人など特定のグループに対する複数回接種の必要性が相まって、市場成長の妨げになると予想されます。これらの人々にとって、完全な免疫を獲得するために2回の接種が必要であることは、全体的な費用を大幅に増加させる可能性があり、追加的な経済的負担による保護者の懸念につながっています。

ワクチンは通常1回分ずつバイアルで投与されるため、特にインフルエンザに感染するリスクが低いと認識されている場合には、追加費用がワクチン接種を思いとどまらせる可能性があります。さらに、ワクチンの価格が高いため、政府や保険会社が経済的な責任を負うことになり、特にインフルエンザが大流行した場合、ヘルスケアシステムに負担がかかる可能性があります。これらの要因により、ワクチン接種率が全体的に制限され、インフルエンザワクチン市場の成長が鈍化する可能性が高いです。

当レポートでは、世界のインフルエンザワクチン市場について調査し、市場の概要とともに、タイプ別、用途別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析

第4章 戦略的洞察と業界見通し

• 市場のリーダーとパイオニア
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向
• キーオピニオンリーダー

第5章 インフルエンザワクチン市場（タイプ別）

• 不活化ワクチン
• 生弱毒化ワクチン
• 組み換えワクチン

第6章 インフルエンザワクチン市場（用途別）

• 3歳未満の幼児
• 成人と3歳以上の小児

第7章 インフルエンザワクチン市場、地域別市場分析と成長機会

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他
• 中東・アフリカ

第8章 競合情勢と市場ポジショニング

• 競合状況の概要と主要市場参入企業
• 市場シェア分析とポジショニングマトリックス
• 戦略的パートナーシップ、合併・買収
• 製品ポートフォリオとイノベーションにおける主な発展
• 企業ベンチマーク

第9章 企業プロファイル

• AstraZeneca
• 会社概要
• 製品ポートフォリオ
• 財務概要
• 主な発展
• SWOT分析
• Sanofi
• CSL
• Serum Institute of India Pvt. Ltd
• Viatris Inc.
• Hualan Biological Engineering Inc
• Sinovac Biotech Ltd.
• GSK Plc
• Pfizer Inc.
• CureVac NV

第10章 前提と調査手法

第11章 付録

The global flu vaccine market reached US$ 5.70 billion in 2024 and is expected to reach US$ 10.74 billion by 2033, growing at a CAGR of 7.3% during the forecast period 2025-2033.

Flu vaccines are vaccines that protect the body from influenza viruses. Healthcare providers infuse the vaccine into muscles or skin, encouraging the immune system to produce antibodies to the influenza virus. Medical professionals administer the "flu shot" vaccine as a single dose of liquid injected through the skin into the muscle. There are different types of flu vaccines, including inactivated vaccines, live attenuated vaccines, and recombinant vaccines.

Market Dynamics: Drivers & Restraints

Increasing Product Innovations

The introduction of innovative vaccines, including those offering broader protection against a wider range of influenza strains, is expected to create a positive impact on the growth of the flu vaccine market. These advancements, such as adjuvanted vaccines, enhance immune responses and can lead to longer-lasting protection, potentially reducing the need for frequent vaccinations.

Companies are actively developing these novel vaccines to provide better protection for a larger population. For example, in October 2023, Mylab and Serum Institute of India (SII) launched Nasovac S4, India's first needle-free nasal influenza vaccine, which targets four influenza virus strains in line with WHO recommendations.

Additionally, in September 2023, Cadila Pharmaceuticals introduced the Cadiflu Tetra Vaccine, an advanced quadrivalent influenza vaccine aimed at preventing widespread influenza infections. These innovations are likely to attract the attention of healthcare providers and individuals, boosting demand for efficient immunization solutions and driving market growth during the forecast period.

High Cost of the Product Coupled with the Dosage of the Vaccine

The high cost of flu vaccines, combined with the need for multiple doses for certain groups, such as children under a specific age or those who have not been previously immunized, is expected to hinder market growth. For these individuals, the requirement for two doses to achieve full immunity can significantly increase overall costs, leading to concerns among parents due to the additional financial burden.

As vaccines are typically administered in single-dose vials, the added expense may discourage vaccination, particularly if individuals perceive themselves to be at low risk of contracting the flu. Furthermore, the high price of vaccines could prompt governments and insurance companies to bear more of the financial responsibility, which may place strain on healthcare systems, especially in the event of flu outbreaks. These factors are likely to limit overall vaccination rates, slowing the growth of the flu vaccine market.

Segment Analysis

The global flu vaccine market is segmented based on type, application, and region.

Type:

Inactivated Vaccines in the type segment is expected to dominate the flu vaccine market.

The inactivated vaccines segment is expected to maintain its dominant position in the global flu vaccine market throughout the forecast period. These vaccines are known for their established safety profile, as they contain a dormant virus that cannot cause the flu. Inactivated vaccines are highly effective at stimulating the immune system to produce antibodies against the flu virus, offering protection against specific strains. The manufacturing technology for inactivated vaccines, particularly split viral vaccines, is well-established, allowing for efficient and cost-effective production compared to newer vaccine technologies that are still under development.

Inactivated vaccines are generally safe for most individuals, including adults, older children, pregnant women, and those with weakened immune systems (with certain exceptions), making them a versatile option for mass immunization campaigns. While research and development are increasingly focused on creating universal vaccines that can offer broad protection against multiple influenza strains, these vaccines are still in the early stages. Therefore, inactivated vaccines will continue to play a crucial role in flu prevention, ensuring the segment's dominance in the market during the forecast period.

Geographical Analysis

North America is expected to dominate the flu vaccine market.

North America is expected to maintain its dominant position in the global flu vaccine market due to several key factors. Increased government initiatives, including health programs aimed at raising awareness about influenza, its potential impacts, and the importance of flu vaccination, are driving market growth in the region. Additionally, the region benefits from a highly developed healthcare infrastructure and favorable reimbursement policies, further boosting market expansion.

A significant number of major pharmaceutical companies are also advancing clinical trials to offer a wide range of flu vaccine options, thereby enhancing their portfolios and increasing accessibility for individuals. In the U.S., government support for the development of effective vaccines that can serve large populations plays a critical role. For instance, in May 2023, a clinical trial began for an experimental universal influenza vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID), with volunteers enrolling at Duke University.

Similarly, in September 2023, the NIH launched a Phase I trial for a broader "universal" flu vaccine. Additionally, Pfizer Inc. initiated the first Phase 3 clinical trial of its quadrivalent modified RNA (modRNA) influenza vaccine in 2022, demonstrating ongoing advancements in vaccine technology.

These factors, combined with strong research and development efforts, are expected to keep North America at the forefront of the flu vaccine market throughout the forecast period.

Competitive Landscape

The global market players in the flu vaccine market include AstraZeneca, Sanofi, CSL, Serum Institute of India Pvt. Ltd, Viatris Inc., Hualan Biological Engineering Inc., Sinovac Biotech Ltd., GSK Plc, Pfizer Inc., and CureVac N.V., among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming pharmaceutical advancements.
• Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global flu vaccine market report would provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Type
• 2.4. Snippet by Application
• 2.5. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Increasing Product Innovations
    • 3.1.1.2. Rising Collaborations among Key Players
  • 3.1.2. Restraints
    • 3.1.2.1. High Cost of the Product Coupled with the Dosage of the Vaccine
    • 3.1.2.2. Stringent Regulatory Framework
  • 3.1.3. Opportunity
    • 3.1.3.1. Technological Advancements in Vaccine Discovery
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with the largest selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia Pacific
  • 4.5.4. South America
  • 4.5.5. Middle East & Africa
• 4.6. Porter's Five Force Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Flu Vaccine Market, By Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 5.1.2. Market Attractiveness Index, By Type
• 5.2. Inactivated Vaccines*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 5.3. Live Attenuated Vaccines
• 5.4. Recombinant Vaccines

6. Flu Vaccine Market, By Application

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 6.1.2. Market Attractiveness Index, By Application
• 6.2. Children < 3 Years*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Adults and Children > 3 years

7. Flu Vaccine Market, By Regional Market Analysis and Growth Opportunities

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 7.1.2. Market Attractiveness Index, By Region
• 7.2. North America
  • 7.2.1. Introduction
  • 7.2.2. Key Region-Specific Dynamics
  • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.2.5.1. U.S.
    • 7.2.5.2. Canada
    • 7.2.5.3. Mexico
• 7.3. Europe
  • 7.3.1. Introduction
  • 7.3.2. Key Region-Specific Dynamics
  • 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.3.5.1. Germany
    • 7.3.5.2. U.K.
    • 7.3.5.3. France
    • 7.3.5.4. Spain
    • 7.3.5.5. Italy
    • 7.3.5.6. Rest of Europe
• 7.4. South America
  • 7.4.1. Introduction
  • 7.4.2. Key Region-Specific Dynamics
  • 7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.4.5.1. Brazil
    • 7.4.5.2. Argentina
    • 7.4.5.3. Rest of South America
• 7.5. Asia-Pacific
  • 7.5.1. Introduction
  • 7.5.2. Key Region-Specific Dynamics
  • 7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.5.5.1. China
    • 7.5.5.2. India
    • 7.5.5.3. Japan
    • 7.5.5.4. South Korea
    • 7.5.5.5. Rest of Asia-Pacific
• 7.6. Middle East and Africa
  • 7.6.1. Introduction
  • 7.6.2. Key Region-Specific Dynamics
  • 7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

8. Competitive Landscape and Market Positioning

• 8.1. Competitive Overview and Key Market Players
• 8.2. Market Share Analysis and Positioning Matrix
• 8.3. Strategic Partnerships, Mergers & Acquisitions
• 8.4. Key Developments in Product Portfolios and Innovations
• 8.5. Company Benchmarking

9. Company Profiles

• 9.1. AstraZeneca*
  • 9.1.1. Company Overview
  • 9.1.2. Product Portfolio
    • 9.1.2.1. Product Description
    • 9.1.2.2. Product Key Performance Indicators (KPIs)
    • 9.1.2.3. Historic and Forecasted Product Sales
    • 9.1.2.4. Product Sales Volume
  • 9.1.3. Financial Overview
    • 9.1.3.1. Company Revenue
    • 9.1.3.2. Geographical Revenue Shares
    • 9.1.3.3. Revenue Forecasts
  • 9.1.4. Key Developments
    • 9.1.4.1. Mergers & Acquisitions
    • 9.1.4.2. Key Product Development Activities
    • 9.1.4.3. Regulatory Approvals, etc.
  • 9.1.5. SWOT Analysis
• 9.2. Sanofi
• 9.3. CSL
• 9.4. Serum Institute of India Pvt. Ltd
• 9.5. Viatris Inc.
• 9.6. Hualan Biological Engineering Inc
• 9.7. Sinovac Biotech Ltd.
• 9.8. GSK Plc
• 9.9. Pfizer Inc.
• 9.10. CureVac N.V.

LIST NOT EXHAUSTIVE

10. Assumptions and Research Methodology

• 10.1. Data Collection Methods
• 10.2. Data Triangulation
• 10.3. Forecasting Techniques
• 10.4. Data Verification and Validation

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us